Allogeneic CD7-targeting cell therapy for relapsed leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental treatment using donor immune cells engineered to find and attack cancer cells with the CD7 marker. It is for people whose leukemia (T-ALL/LBL or AML) has come back or not responded to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 14 or older.
- You must have T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) or acute myeloid leukemia (AML) that is relapsed or refractory.
- Your cancer cells must test positive for CD7 (a specific protein on the cell surface).
- Your organs (liver, kidneys, heart, lungs) must be working well enough, as checked by blood tests and scans.
- You must not have had any prior CAR-T cell therapy.
- You must agree to use effective contraception if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune therapy called CD7 CAR-T cells for people with acute leukemia that has come back or hasn't gotten better with standard treatments. It aims to see if this treatment is safe and can help control the leukemia.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a specific marker called CD7 on blood cancer cells. It is for people whose blood cancer has not responded to other treatments or has come back after treatment.
This trial tests a new immune cell therapy (CD7 CAR-T) given as a bridge to a stem cell transplant in people with relapsed or hard-to-treat CD7-positive leukemia. The goal is to help control the leukemia and improve chances for a successful transplant.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.